news
Novel microneedle array developed to deliver COVID-19 vaccine to mice
Researchers have created a microneedle array that successfully delivered a COVID-19 vaccine to mice, allowing them to produce antibodies against the virus.
List view / Grid view
Antibodies
news
Study evaluates if siltuximab benefits COVID-19 patients with respiratory complications
The SISCO study will assess if the anti-IL-6 antibody siltuximab can aid patients suffering Acute Respiratory Distress Syndrome as a complication of the COVID-19 coronavirus.
news
Clinical programme to evaluate Kevzara® as COVID-19 treatment begins
Led by Sanofi and Regeneron, clinical trials to examine Kevzara (sarilumab) as an effective COVID-19 treatment will begin in the US.
news
Drug delivery method leads to sustained HIV antibody production in study
Using AAV-based technology to deliver mAbs in a Phase I trial, researchers report that participants successfully developed antibodies against HIV.
news
Development initiated for a plasma-derived COVID-19 therapy
An anti-SARS-CoV-2 polyclonal hyperimmune globulin (H-IG) is being developed to treat infected, high-risk individuals with COVID-19.
news
Gilead set to acquire Forty Seven for $4.9bn later in 2020
Gilead's acquisition of Forty Seven was unanimously approved by both companies' Boards of Directors, for $95.50 per share.
news
Thin film platform to preserve vaccines at room temperature developed
A new vaccine formulation has been created by researchers, which uses a peelable film during drying to preserve the medicine.
news
Coronavirus update: clinical trials and antibody manufacture
The US NIH has initiated a clinical trial for remdesivir and two pharmaceutical companies will work together to manufacture antibody treatments to tackle the coronavirus.
news
Lilly announces agreement to acquire Dermira for $1.1bn
Eli Lilly has announced it is to acquire Dermira for $18.75 per share, or approximately $1.1 billion, which will expand Lilly's immunology pipeline.
article
How can NMR spectroscopy help protein biopharmaceutical development?
Nuclear magnetic resonance (NMR) spectroscopy is a technique that most have heard of but many avoid, especially when dealing with larger biological macromolecules. Why? The common wisdom is that NMR can be complicated, expensive and involves quantum physics and complex equations. In the fast-paced industrial biopharmaceutical environment there may be…
article
Using plants as bioreactors to produce proteins for therapeutics
European Pharmaceutical Review explores how plants can be used for large-scale, glycosylated protein bioproduction for the pharma industry.
news
Keytruda® (pembrolizumab) with chemotherapy meets Phase III PFS endpoint
The drug’s developers reveal Keytruda increased progression-free survival (PFS) in patients with metastatic triple-negative breast cancer (mTNBC) expressing PD-L1.
news
FDA approves Keytruda for patients with high-risk, non-muscle invasive bladder cancer
Keytruda is the first anti-PD-1 monoclonal antibody therapy approved for patients with BCG-unresponsive, high-risk, non-muscle invasive bladder cancer.
news
First company awarded market authorisation under new Chinese drug law
The mAb tislelizumab has been granted approval from Chinese authorities, making Boehringer Ingelheim Biopharmaceuticals the first MAH under the new system.
news
WHO announces first biosimilar medicine pre-qualification
A trastuzumab biosimilar has been pre-qualified by WHO, marking its first, to improve access to the breast cancer treatment.
